Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 15/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.48 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1569224 | 0.86 | PSMB5 (0.60) | PSMB5POLBKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL653251 | 0.74 | ALOX15 (0.65) | POLBKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL12216376 | 0.73 | PSMB5 (0.55) | PSMB5ALDH1A1SMN1; SMN2TRPM8 | |
| SCHEMBL23358696 | 0.72 | POLB (0.69) | POLBSMN1; SMN2TRPM8 | |
| SCHEMBL2795176 | 0.71 | POLB (0.58) | POLBKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL23605977 | 0.69 | MAPT (0.67) | POLBKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL13382671 | 0.69 | POLB (0.54) | POLBKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL12378826 | 0.69 | ALDH1A1 (0.58) | POLBKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL16438577 | 0.69 | POLB (0.59) | POLBKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL6539987 | 0.68 | SRD5A2 (0.91) | ALDH1A1SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257176-A1 | NITROGEN HETEROCYCLE DERIVATIVES AS PROTEASOME MODULATORS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2011-10-20 | — | — | US | disclosed |
| US-20110257176-A1 | NITROGEN HETEROCYCLE DERIVATIVES AS PROTEASOME MODULATORS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2011-10-20 | — | — | US | disclosed |
| US-20110257176-A1 | NITROGEN HETEROCYCLE DERIVATIVES AS PROTEASOME MODULATORS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2011-10-20 | — | — | US | disclosed |
| EP-2307012-A1 | NITROGEN HETEROCYCLE DERIVATIVES AS PROTEASOME MODULATORS | Institut National De La Sante Et De La Recherche Medicale (FR) | 2011-04-13 | — | — | EP | disclosed |
| WO-2010001365-A1 | NITROGEN HETEROCYCLE DERIVATIVES AS PROTEASOME MODULATORS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2010-01-07 | — | — | WO | disclosed |
| WO-2010001365-A1 | NITROGEN HETEROCYCLE DERIVATIVES AS PROTEASOME MODULATORS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257176-A1 | NITROGEN HETEROCYCLE DERIVATIVES AS PROTEASOME MODULATORS | PSMB1, PSME1, PSMB2 | PSMB5 6/4885POLB 641/4885KDM4E 1843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.